2022. Bimekizumab efficacy through one year in patients with moderate to severe plaque psoriasis in subgroups defined by prior biologic treatment: Pooled results from four phase 3/3b trials . SKIN The Journal of Cutaneous Medicine. 6, 6 (Nov. 2022), s64. DOI:https://doi.org/10.25251/skin.6.supp.64.